A recovery category is not a clinical indication
BPC-157, TB-500, copper peptides and thymosin-alpha-1 need different identity records. For TB-500, resolve fragment versus full-length naming; for copper peptides, distinguish the intended formulation and route.
Make the comparison specific
Compare blends by per-component quantities rather than total mass. FDA's safety discussion includes several substances in this category; laboratory mechanisms and a supplier purity claim do not establish patient benefit, sterility or a permitted supply pathway.
Regulatory context: FDA: substance-specific safety concerns. Source reviewed . This source does not verify the identity, testing or availability of our catalog references.
Related guidance: Evidence review before expanding a clinic menu. These references support a review, not a treatment recommendation or supply authorization.